Next results · Q4 2026Projected
Mar 22, after the close
Mon, Mar 22, 2027in 125 days
Projected from its last 8 releases. The company has not named the day yet.
- Quarter
- Q4 2026 · Ends about Dec 31, 2026
- 10-K window
- Mar 10 – Apr 2
Read against Q4 2025
The same quarter a year earlier, the figures the next ones will be compared with. Thaler holds no estimates.
- Revenue
- $11.65M
- Revenue, change from a year earlier: Q3 2026 −6.1%, Q2 2026 −84.6%, Q1 2026 −16.5%, Q4 2025 −21.4%
- Net income
- -$46.76M
- Net income, change from a year earlier: Q3 2026 n/m, Q2 2026 n/m, Q1 2026 n/m, Q4 2025 n/m
- EPS
- —
- EPS, change from a year earlier: Q3 2026 n/m, Q2 2026 n/m, Q1 2026 n/m, Q3 2025 n/m
Results day
Typical moveA typical move of 12.8% either way
Up after 2 of 4, down after 2.
The stock’s move from the last close before each release to the first close after it, over the last 4 releases. Largest: −15.2% after Q2 2026.
Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.
When it reports
- Usual day
- Thursday
- 6 of its last 8
- Session
- after the close
- After quarter end
- 38 to 72 days
- 10-Q filed
- 38 to 44 days
- over its last 8
- 10-K filed
- 72 to 89 days
- over its last 8
Based on 8 prior 10-K filings.
Sutro Biopharma, Inc. · CIK 1382101 · Engraved from SEC EDGAR